Restriction on Emergency Contraceptive Prescription for Under 17s... Recommendation for In-Person Consultation

Olacare Strengthens 'Prescription Restriction System' to Prevent Adolescent Drug Abuse View original image


[Asia Economy Reporter Lee Gwanju] Olacare, a non-face-to-face medical consultation and medication delivery platform, announced on the 13th that it will establish and strengthen a prescription restriction system to prevent drug misuse among adolescents.


The newly announced prescription restriction system was created to proactively establish voluntary regulatory standards in response to concerns in the medical community regarding drug misuse and personal sensitive information leakage in non-face-to-face medical consultations and prescriptions.


Notably, Olacare is the first in the industry to introduce a system that restricts the prescription of emergency contraceptives to adolescents under the age of 17 to prevent drug misuse among youth.


When adolescents under 17 select the "emergency contraception" condition on the Olacare consultation application screen, a popup message stating "For minors, emergency contraception consultation is recommended to be conducted face-to-face" appears, and the application is restricted. Additionally, if the adolescent selects other conditions and requests emergency contraceptive prescriptions during the non-face-to-face consultation, the attending physician will guide them to visit a hospital for an in-person consultation.


Emergency contraceptives contain hormone levels approximately 10 times higher, which can cause various side effects in adolescents such as headaches, irregular bleeding, vomiting, and menstrual irregularities. It is also known that misuse can increase the risk of infertility and subfertility.



Kim Seonghyun, CEO of BlueAnt, which operates Olacare, said, "If a patient receives follow-up or non-face-to-face consultations in the same or different departments, doctors participating on the platform can check the patient's medical history, preventing drug misuse in advance," adding, "We will continue to improve the voluntary regulatory standards and systems we have created to address concerns raised by some parties."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing